Peptidomimetics and Stapled Peptides Explained

In plain English

A short peptide in water is not one shape; it is an ensemble of many. It is also a substrate: peptidases recognise the regular backbone and cut it. Both facts limit what a plain chain can do in a laboratory experiment.

Peptidomimetic chemistry answers both at once. Change the backbone, or tie two side chains together, and the chain holds a defined conformation and stops looking like a peptidase substrate ^[1].

A review of the field groups the tools into three levels: local modifications at one residue, global restrictions such as cyclisation, and secondary-structure mimetics that reproduce a helix or a turn with non-peptide scaffolding ^[1].

A stapled peptide is the best-known example of the second group. Two residues on the same face of a helix are joined by a covalent bridge, most often an all-hydrocarbon one made by ring-closing olefin metathesis ^{[2, 3, 4]}.

The short version

• Peptidomimetics trade peptide chemistry for a fixed shape and protease resistance ^[1].
• Changes range from one methyl group to a whole new backbone ^{[1, 5, 8]}.
• A staple is a covalent cross-link that holds a helix in shape ^{[2, 3, 4]}.

Key facts

Local changes: one residue at a time

The smallest peptidomimetic changes leave the chain recognisably a peptide.

N-methylation places a methyl group on a backbone amide nitrogen. The inspiration is natural: cyclosporine is a multiply N-methylated cyclic peptide. A programme of work on multiple N-methylation produced a complete library of N-methylated cyclic alanine pentapeptides, which mapped how methylation patterns alter the conformational behaviour of cyclic peptides, and reported that multiple N-methylation can markedly improve metabolic stability ^[5].

D-residues change configuration without changing composition. Proteases are stereospecific, so a D-substituted backbone is a poor substrate. In a systematic comparison, each L-residue sequence was readily cleaved by its matching enzyme — chymotrypsin, elastase, papain, pepsin, trypsin or carboxypeptidase A — while the equivalent D-residue oligomers were cleaved minimally or not at all ^[6]. The stereochemistry behind this is covered in Chirality in Peptides.

Retro-inverso design combines the two ideas: reverse the direction in which the backbone is read and invert the configuration of every residue, so that the side chains end up in roughly their original spatial arrangement while the amide bonds point the other way ^[7]. The approach is described as a topochemical exploration, because what is conserved is the topology of the side chains rather than the chemistry of the backbone ^[7].

Amide-bond surrogates replace the peptide bond itself with a group of similar geometry, a standard part of the local-modification toolbox described in the peptidomimetic review ^[1].

Whole-backbone replacements

Further along the scale, the backbone stops being a peptide backbone.

Peptoids are oligomers of N-substituted glycines: the side chain hangs from the backbone nitrogen rather than from the α-carbon ^{[8, 9]}. That single move removes the backbone hydrogen-bond donor and the α-stereocentre. Calculated Ramachandran-type plots indicated a greater diversity of conformational states available to peptoids than to peptides, and peptoid versions of peptide ligands for three biological systems were found with affinities comparable to the corresponding peptides ^[8]. Peptoid synthesis is also convenient: the submonomer route builds each residue from a haloacetic acid and a primary amine on solid support, so diversity comes from a catalogue of amines rather than from protected amino acids ^[9]. In the proteolysis comparison above, the N-substituted glycine oligomers resisted the same enzymes that cleaved the L-residue sequences ^[6].

Beta- and gamma-peptides insert one or two extra methylene groups into each residue’s backbone. The protease result here is unusually clean. Thirty-six linear and cyclic beta- and gamma-peptides, from two to fifteen residues, were offered to fifteen commercially available peptidases of bacterial, fungal and eukaryotic origin, including the human 20S proteasome. Under conditions that completely cleaved a reference α-peptide within 15 minutes, the beta- and gamma-peptides were stable for at least 48 hours, and inhibition studies showed they did not inhibit the enzymes either ^[10].

These oligomers belong to the wider class Gellman named foldamers: synthetic oligomers designed to adopt specific, compact conformations, set out as a research programme in its own right ^[12].

Stapled peptides

An α-helix is held together by backbone hydrogen bonds. Cut a helical segment out of a protein and it usually loses that structure, because the rest of the protein was part of what held it. A staple restores the constraint chemically.

How the staple is made

The enabling reaction is ring-closing olefin metathesis (RCM). Blackwell and Grubbs showed that carbon–carbon tethers could be introduced between amino acid side chains by RCM, giving macrocyclic helical peptides under mild conditions ^[4]. Schafmeister, Po and Verdine then developed the all-hydrocarbon cross-linking system that gives the method its present form, reporting enhanced helicity and metabolic stability ^[2].

A published procedure sets out the two essential elements: α-methyl, α-alkenyl amino acids placed at chosen positions, and ring-closing metathesis of the resulting resin-bound peptide. The described systems bridge either one or two turns of a helix, are adaptable to most sequences, and the paper reports favourable RCM kinetics, helix stabilisation and promotion of cellular uptake ^[3].

Where the staple goes

Position is not arbitrary. An α-helix turns roughly every 3.6 residues, so residues at i and i+4 sit on the same face one turn apart, and residues at i and i+7 sit on the same face two turns apart. Those are the spacings the hydrocarbon stapling systems are built around ^[3].

The lactam-bridge literature shows how sharply geometry matters. In a series of 14-residue amphipathic helical peptides with glutamic acid and lysine side chains joined as a lactam, (i, i+4) bridges forming 21-membered rings were helix-stabilising, while (i, i+3) bridges forming 18-membered rings were helix-destabilising regardless of position — and even among the stabilising ones, the Glu-Lys orientation stabilised the helix while the Lys-Glu orientation destabilised it relative to the unbridged chain. Two Glu-Lys (i, i+4) lactams at the termini gave more than 99% helical content in benign buffer ^[11].

More than one staple

Extending the chemistry, a bis ring-closing metathesis reaction produces stitched peptides: multiple contiguous staples joined by a central spiro ring junction. Circular dichroism, NMR and computational analysis showed remarkable thermal stabilities, and trypsin proteolysis assays confirmed a structural rigidity unmatched by singly stapled peptides ^[13]. Helix content itself is measured as described in Circular Dichroism and Secondary Structure.

What stapling is reported to do

A review written from more than a decade of practice lists what a successful all-hydrocarbon staple confers: α-helical structure, protease resistance, cellular penetrance and biological activity, achieved only when a set of design principles is followed ^[14]. The same review is candid about the pitfalls, which is the more useful half of it: stapling is a design exercise, not a transformation that improves any sequence automatically.

Analytical consequences

Peptidomimetics complicate routine analysis in specific ways.

European guidance on synthetic peptides is written around chains of standard residues, but its general expectation still applies: the control strategy must address related substances arising from both the starting materials and the process, and one chromatographic method rarely separates every related substance ^[15].

What this means in Australia

• A modified molecule is a different molecule. A staple, an N-methyl group or a D-residue changes the substance, not merely its presentation. Identity, purity and content all have to be established for the modified chain itself, not inherited from the parent sequence ^[15].
• Accredited testing. The National Association of Testing Authorities (NATA) accredits Australian laboratories to ISO/IEC 17025, the international standard for the competence of testing and calibration laboratories ^[16]. Non-standard analytes are exactly where method competence matters most.
• Modification does not change legal status. Status under the current Poisons Standard (October 2026) attaches to the substance named there; several peptides are listed in Schedule 4 (prescription only) and Appendix D, clause 5 (possession without authority is illegal) ^[17]. Whether a class entry captures a modified analogue is a legal question, not a chemical one.
• Labels do not change status. The TGA has stated that a “research use only” disclaimer does not make supply lawful, and does not change a product’s regulatory status, permit importation, or remove advertising or supply obligations ^[18].

This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.

Frequently asked questions

What is a peptidomimetic?

A molecule designed to present the same spatial arrangement of groups as a peptide while replacing part of its chemistry. Published approaches are grouped into local modifications, global restrictions such as cyclisation, and secondary-structure mimetics ^[1].

What is a stapled peptide?

A peptide whose helical shape is held by a covalent cross-link between two residues on the same face of the helix, most often an all-hydrocarbon bridge formed by ring-closing olefin metathesis ^{[2, 3, 4]}.

Why are peptidomimetics resistant to proteases?

Because peptidases recognise a regular, stereochemically defined backbone. Change the configuration, move the side chain to the nitrogen or lengthen each residue, and the chain is no longer a good substrate ^{[6, 10]}.

What is a peptoid?

An oligomer of N-substituted glycines: the side chain is attached to the backbone nitrogen instead of the α-carbon. Peptoids have more available conformational states than peptides and are built efficiently by submonomer solid-phase synthesis ^{[8, 9]}.

Does a staple always stabilise a helix?

No. Geometry decides. In the lactam-bridge series, (i, i+4) 21-membered rings were stabilising while (i, i+3) 18-membered rings were destabilising, and even orientation of the bridge reversed the outcome ^[11].

How is helix content measured?

Usually by circular dichroism, which reports the fraction of helical structure in solution. The method is described in Circular Dichroism and Secondary Structure.

References

1. Lenci E, Trabocchi A. Peptidomimetic toolbox for drug discovery. Chem Soc Rev. 2020;49(11):3262–3277. doi:10.1039/d0cs00102c. PMID: 32255135
2. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc. 2000;122(24):5891–5892. doi:10.1021/ja000563a
3. Kim YW, Grossmann TN, Verdine GL. Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat Protoc. 2011;6(6):761–771. doi:10.1038/nprot.2011.324. PMID: 21637196
4. Blackwell HE, Grubbs RH. Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis. Angew Chem Int Ed Engl. 1998;37(23):3281–3284. doi:10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V. PMID: 29711420
5. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res. 2008;41(10):1331–1342. doi:10.1021/ar8000603. PMID: 18636716
6. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WH. Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers. Drug Dev Res. 1995;35(1):20–32. doi:10.1002/ddr.430350105
7. Chorev M, Goodman M. Recent developments in retro peptides and proteins — an ongoing topochemical exploration. Trends Biotechnol. 1995;13(10):438–445. doi:10.1016/S0167-7799(00)88999-4. PMID: 7546569
8. Simon RJ, Kania RS, Zuckermann RN, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A. 1992;89(20):9367–9371. doi:10.1073/pnas.89.20.9367. PMID: 1409642
9. Zuckermann RN, Kerr JM, Kent SBH, Moos WH. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J Am Chem Soc. 1992;114(26):10646–10647. doi:10.1021/ja00052a076
10. Frackenpohl J, Arvidsson PI, Schreiber JV, Seebach D. The outstanding biological stability of beta- and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. Chembiochem. 2001;2(6):445–455. doi:10.1002/1439-7633(20010601)2:6<445::AID-CBIC445>3.0.CO;2-R. PMID: 11828476
11. Houston ME Jr, Gannon CL, Kay CM, Hodges RS. Lactam bridge stabilization of alpha-helical peptides: ring size, orientation and positional effects. J Pept Sci. 1995;1(4):274–282. doi:10.1002/psc.310010408. PMID: 9223005
12. Gellman SH. Foldamers: a manifesto. Acc Chem Res. 1998;31(4):173–180. doi:10.1021/ar960298r
13. Hilinski GJ, Kim YW, Hong J, et al. Stitched α-helical peptides via bis ring-closing metathesis. J Am Chem Soc. 2014;136(35):12314–12322. doi:10.1021/ja505141j. PMID: 25105213
14. Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem. 2014;57(15):6275–6288. doi:10.1021/jm4011675. PMID: 24601557
15. European Medicines Agency. Guideline on the development and manufacture of synthetic peptides. EMA/CHMP/CVMP/QWP/367182/2025. Adopted 4 December 2025; effective 1 June 2026. ema.europa.eu. Accessed 25 October 2026.
16. National Association of Testing Authorities, Australia (NATA). Accreditation programs, including ISO/IEC 17025 testing and calibration. nata.com.au. Accessed 25 October 2026.
17. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation. legislation.gov.au/F2026L01327/latest/text. Accessed 25 October 2026.
18. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 25 October 2026.